Cumberland Pharmaceuticals to Present at UBS Global Life Sciences Conference in New York on September 21, 2009

Thursday, September 17, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+



NASHVILLE, Tenn., Aug. 31 Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Chief Executive Officer A.J. Kazimi will present at the UBS Global Life Sciences Conference in New York at 11:00 a.m. Eastern Time on Monday, September 21, 2009. Mr. Kazimi will provide an update on the Company and its Caldolor product, which Cumberland is preparing to launch following its recent approval by the Food and Drug Administration.

The presentation will be simultaneously webcast and can be accessed by visiting the Investor Relations section on Cumberland Pharmaceuticals' website at www.cumberlandpharma.com. Shortly following the live webcast, a replay will be available and archived for 30 days.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote(R) for the treatment of acetaminophen poisoning and Kristalose(R), a prescription laxative. The Company also recently received FDA approval for Caldolor(R), the first injectable treatment for pain and fever available in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company recently completed an initial public offering of its common stock.

For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.

Statements contained in this press release that are not historical facts are "forwardlooking" statements within the meaning of the federal securities laws. Forward-looking statements are uncertain and subject to a variety of risks that could cause actual results to differ materially from those expected by the Company. Additional information regarding such risks can be found in the Company's Registration Statement declared effective by the SEC on August 10, 2009.

SOURCE Cumberland Pharmaceuticals Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook